Humulin M3 (Mixture 3)

Humulin M3 (Mixture 3) is a prescription injectable solution that contains recombinant human insulin (rDNA) as its active ingredient. It is supplied in standard concentration for intramuscular or subcutaneous administration and is marketed in the European Union. The formulation blends short‑acting and intermediate‑acting insulin to provide basal and prandial glucose control for people with diabetes under medical supervision as part of an individualized treatment regimen.

Humulin M3 is indicated for the management of hyperglycemia in adults with diabetes mellitus.

- Type 1 diabetes mellitus (insulin‑dependent) - Type 2 diabetes mellitus (insulin‑requiring) - Use when a mixed insulin profile is desired to cover both mealtime and basal needs - May be used in combination with oral antidiabetic agents as directed by a healthcare professional - Suitable for patients who require flexibility in injection timing - Can be used in hospital settings for basal‑bolus insulin therapy - May be prescribed for patients transitioning from separate regular and NPH insulin injections

Adverse reactions to Humulin M3 may vary in frequency and severity.

Common: - Hypoglycemia (low blood glucose) - Injection site reactions (redness, swelling, itching) - Lipodystrophy (localized fat changes) - Weight gain

Serious: - Severe hypoglycemia with loss of consciousness or seizures - Allergic reactions such as urticaria, angioedema or anaphylaxis - Acute metabolic acidosis (rare)

When prescribing or using Humulin M3, clinicians and patients should consider several safety precautions.

- Monitor blood glucose regularly to avoid hypoglycemia - Adjust dose during periods of illness, stress, or changes in physical activity - Use caution in patients with renal or hepatic impairment, as insulin clearance may be reduced - Avoid use in individuals with known hypersensitivity to human insulin or any excipients - Consider pregnancy and lactation status; insulin requirements may change - Review concomitant medications that affect glucose metabolism - Educate patients on proper injection technique and site rotation

Humulin M3 can interact with other medicines that influence blood glucose or insulin action.

Avoid: - Use of other rapid‑acting insulins without adjusting total insulin dose - Beta‑blockers that can blunt hypoglycemia warning signs - MAO‑A inhibitors that may amplify insulin’s glucose‑lowering effect

Use with caution: - Sulfonylureas or meglitinides, which increase hypoglycemia risk - Corticosteroids, which may raise glucose and require higher insulin doses - Thiazide diuretics, which can affect potassium and glucose balance